A landmark German trial is testing a digital care model designed to evaluate and support patients undergoing cellular therapies. The study will put 306 patients to the test, focusing on survivorship and the post-treatment phase where immune reconstitution, infection risk, and graft-versus-host disease can complicate outcomes. The trial framing addresses a practical bottleneck in cell therapy: survival may depend not only on product efficacy, but on real-world management protocols that standardize follow-up, monitoring, and interventions. As allogeneic transplant and CAR T use expands, digital monitoring and structured care pathways are increasingly positioned as operational levers for improving continuity of care and potentially reducing complications.